Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | June 05, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 74,497 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 74,497 · Balance 74,497 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
RECURSION PHARMACEUTICALS, INC.
Report date June 05, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 883,735 |
Ending reported balance
After 2026-06-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-05 · Conversion · Acquired 40,000 · Balance 923,735 F1: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a sale of the shares by the Reporting Person. Each share of Class B Common Stock is convertible into one share of Class A Common Stock. F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Row 2 · 2026-06-05 · Sale · Disposed 40,000 · Balance 883,735 F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,263,334 |
Reported balance
After 2026-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-05 · Conversion · Disposed 40,000 · Balance 4,263,334 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a sale of the shares by the Reporting Person. Each share of Class B Common Stock is convertible into one share of Class A Common Stock. F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Indirectby LAHWRAN-3 LLC | 386,000 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 386,000 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F4: The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Indirectby LAHWRAN-4 LLC | 388,000 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 388,000 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F5: The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Indirectby Gibson Family Trust | 50,000 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 50,000 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6: The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2035-02-03 | Direct | 1,050,567 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 1,050,567 F7: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.09 · Expires 2034-02-09 | Direct | 666,898 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 666,898 F8: The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2033-02-01 | Direct | 813,600 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 813,600 F9: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 399,002 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 399,002 F10: The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 5,436 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 5,436 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2030-12-30 | Direct | 282,500 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 282,500 F11: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a sale of the shares by the Reporting Person. Each share of Class B Common Stock is convertible into one share of Class A Common Stock.
F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F4: The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
F5: The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
F6: The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
F7: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F8: The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F9: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F10: The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F11: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2025 Filed Dec 6, 2025 00:20 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000016 · wk-form4_1764980406.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 973,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 00:37 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 40,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000014 · wk-form4_1763599043.xml · derivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,823,334 Underlying: Class A Common Stock · 40,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F3 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 00:37 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 40,000 | $4.16 | $166,400.00 |
DisclosureSEC source: 0001856369-25-000014 · wk-form4_1763599043.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 913,839 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 00:37 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000014 · wk-form4_1763599043.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 953,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F3 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 00:37 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 40,390 | $4.14 | $167,214.60 |
DisclosureSEC source: 0001856369-25-000014 · wk-form4_1763599043.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 913,839 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 60,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000012 · wk-form4_1762464222.xml · derivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,863,334 Underlying: Class A Common Stock · 60,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GiftClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000012 · wk-form4_1762464222.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 954,229 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 40,000 | $5.21 | $208,400.00 |
DisclosureSEC source: 0001856369-25-000012 · wk-form4_1762464222.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 974,229 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| November 04, 2025 Filed Nov 6, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000012 · wk-form4_1762464222.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,014,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| October 23, 2025 Filed Oct 24, 2025 22:49 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000010 · wk-form4_1761346138.xml · derivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,923,334 Underlying: Class A Common Stock · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| October 23, 2025 Filed Oct 24, 2025 22:49 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 100,000 | $5.70 | $570,000.00 |
DisclosureSEC source: 0001856369-25-000010 · wk-form4_1761346138.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 954,229 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| October 23, 2025 Filed Oct 24, 2025 22:49 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000010 · wk-form4_1761346138.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,054,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| October 10, 2025 Filed Oct 10, 2025 22:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 120,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000007 · wk-form4_1760133788.xml · derivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,133,034 Underlying: Class A Common Stock · 120,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| October 10, 2025 Filed Oct 10, 2025 22:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GiftClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000007 · wk-form4_1760133788.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 954,229 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| October 10, 2025 Filed Oct 10, 2025 22:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 100,000 | $6.04 | $604,000.00 |
DisclosureSEC source: 0001856369-25-000007 · wk-form4_1760133788.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 974,229 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| October 10, 2025 Filed Oct 10, 2025 22:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000007 · wk-form4_1760133788.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,074,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| September 25, 2025 Filed Sep 26, 2025 22:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 0 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000005 · wk-form4_1758925918.xml · derivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,253,034 Underlying: Class A Common Stock · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| September 25, 2025 Filed Sep 26, 2025 22:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 100,000 | $4.76 | $476,000.00 |
DisclosureSEC source: 0001856369-25-000005 · wk-form4_1758925918.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 954,229 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| September 25, 2025 Filed Sep 26, 2025 22:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001856369-25-000005 · wk-form4_1758925918.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,054,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:24 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 120,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000145 · wk-form4_1757708640.xml · derivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,253,034 Underlying: Class A Common Stock · 120,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:24 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GiftClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000145 · wk-form4_1757708640.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 954,229 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F3 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a bona-fide gift of shares by the Reporting Person. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:24 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 100,000 | $4.71 | $471,000.00 |
DisclosureSEC source: 0001601830-25-000145 · wk-form4_1757708640.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 974,229 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:24 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000145 · wk-form4_1757708640.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,074,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| August 26, 2025 Filed Aug 29, 2025 00:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000136 · wk-form4_1756425654.xml · derivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,373,034 Underlying: Class A Common Stock · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| August 26, 2025 Filed Aug 29, 2025 00:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 100,000 | $4.84 | $484,000.00 |
DisclosureSEC source: 0001601830-25-000136 · wk-form4_1756425654.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 954,229 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| August 26, 2025 Filed Aug 29, 2025 00:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000136 · wk-form4_1756425654.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,054,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 22:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 40,390 | $5.64 | $227,799.60 |
DisclosureSEC source: 0001601830-25-000132 · wk-form4_1755642123.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 954,229 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 17,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000130 · wk-form4_1755133392.xml · derivative · entry 10 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Gibson Family Trust Disclosed balance after: 50,000 Underlying: Class A Common Stock · 17,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F6 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F5 · ownership.nature: The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000130 · wk-form4_1755133392.xml · derivative · entry 9 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · by LAHWRAN-3 LLC Disclosed balance after: 386,000 Underlying: Class A Common Stock · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F6 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F4 · ownership.nature: The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 423,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000130 · wk-form4_1755133392.xml · derivative · entry 8 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,473,034 Underlying: Class A Common Stock · 423,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F6 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 17,875 | $5.28 | $94,380.00 |
DisclosureSEC source: 0001601830-25-000130 · wk-form4_1755133392.xml · nonDerivative · entry 7 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Gibson Family Trust Disclosed balance after: 0 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F5 · ownership.nature: The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 17,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000130 · wk-form4_1755133392.xml · nonDerivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Gibson Family Trust Disclosed balance after: 17,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F5 · ownership.nature: The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 100,000 | $5.28 | $528,000.00 |
DisclosureSEC source: 0001601830-25-000130 · wk-form4_1755133392.xml · nonDerivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · by LAHWRAN-3 LLC Disclosed balance after: 0 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F4 · ownership.nature: The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000130 · wk-form4_1755133392.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · by LAHWRAN-3 LLC Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F4 · ownership.nature: The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GiftClass A Common Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000130 · wk-form4_1755133392.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 994,619 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. F3 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a bona-fide gift of shares by the Reporting Person Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 500,300 | $5.28 | $2,641,584.00 |
DisclosureSEC source: 0001601830-25-000130 · wk-form4_1755133392.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,004,619 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 423,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000130 · wk-form4_1755133392.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,504,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:44 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 36,197 | $4.25 | $153,837.25 |
DisclosureSEC source: 0001601830-25-000082 · wk-form4_1747687435.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,081,253 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| March 27, 2025 Filed Mar 28, 2025 20:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 138,574 | $6.04 | $836,986.96 |
DisclosureSEC source: 0001601830-25-000051 · wk-form4_1743195171.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,117,450 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2024. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 21:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000037 · wk-form4_1741382181.xml · derivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,896,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 21:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $6.37 | $127,400.00 |
DisclosureSEC source: 0001601830-25-000037 · wk-form4_1741382181.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,256,024 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 21:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000037 · wk-form4_1741382181.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,276,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000037 · wk-form4_1741382181.xml · derivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,916,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $6.58 | $131,600.00 |
DisclosureSEC source: 0001601830-25-000037 · wk-form4_1741382181.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,256,024 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000037 · wk-form4_1741382181.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,276,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 17,132 | $10.64 | $182,284.48 |
DisclosureSEC source: 0001601830-25-000020 · wk-form4_1740087766.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,256,024 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000014 · wk-form4_1738962869.xml · derivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,936,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a bona-fide gift of shares by the Reporting Person F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $8.12 | $162,400.00 |
DisclosureSEC source: 0001601830-25-000014 · wk-form4_1738962869.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,273,156 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000014 · wk-form4_1738962869.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,293,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a bona-fide gift of shares by the Reporting Person F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000014 · wk-form4_1738962869.xml · derivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,956,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a bona-fide gift of shares by the Reporting Person F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.